Matthias Tschöp is the CEO of Helmholtz Munich, VP of the Helmholtz Association and AvH Professor at the TU of Munich. He unraveled fundamental gut-brain signals to discover the first highly effective drugs for human obesity in collaboration with the chemist Richard DiMarchi – the dual and triple gut hormone multi-agonists. A first representative is FDA-approved. Tschöp has received numerous awards, including the Banting Medal, the Heinrich Wieland Prize and the Ernst Jung Prize. He holds an adjunct professorship at Yale University and an honorary doctorate at Leipzig University. He was elected a member of the German, Bavarian, and European Academies of Sciences, the ASCI and the AAP.